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Purpose: Angiogenesis plays an important role in the
growth, progression, and metastasis of tumors. Vascular
endothelial growth factor (VEGF) overexpression has been
associated with advanced stage and poor survival in several
cancers. We investigated the present case-control study to
determine whether there is an association between the VEGF
936C > T polymorphism and stomach cancer. Patients and
Methods: The association of functional single nucleotide poly-
morphisms (SNPs) of the VEGF gene with stomach cancer
development was evaluated in a case-control study of 154
Korean stomach cancer patients. Genotypes were determined
by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) analysis. Results: Our results
revealed significant association of T allele-bearing genotypes
with increased risk for stomach cancer development. Genotype
frequencies of the VEGF 936C > T polymorphisms were
significantly different between patient and control groups (CT,
AOR: 2.007, 95% CI: 1.277- 3.156, TT, AOR: 4.790, 95% CI:
1.174 -19.539, CT + TT, AOR: 2.147, 95% CI: 1.382 - 3.337).
When stratified by gender and age, genotype frequencies were
significantly different for stomach cancer in women and in
patients younger than 55 years (in women, CT, OR: 3.049,
95% CI: 1.568 - 5.930, CT+TT, OR: 3.132, 95% CI: 1.638 -
5.990; in < 55 years, CT, OR: 3.306, 95% CI: 1.413 - 7.732,
CT + TT, OR: 3.967, 95% CI: 1.729 -9.104). In addition, this
association partially remained in cases with intestinal and
diffuse-type stomach cancer. Conclusion: Our present study
suggests that the VEGF 936C > T polymorphism is a
susceptibility factor for stomach cancer, at least in Korean.
These observations, however, require further confirmation by
a larger multi-ethnic study.
Key Words: Stomach cancer, polymorphism, vascular
endothelial growth factor, Korean
INTRODUCTION
As one of the most common human malignant
tumors, stomach cancer ranks as the first leading
cause of gastrointestinal cancer-related mortality
worldwide.
1 Over the past few years, many
attempts have been made to better define the
biological profile of stomach cancer in order to
improve early diagnosis and prognostic stratifi-
cation, and to find an eventual cure.
2-4
Angiogenesis is an essential step for tumor
growth, playing a critical role in invasion and
metastasis.
5 It is regulated by various growth
factors, among which VEGF plays a central role.
A number of studies have confirmed that VEGF
expression is closely associated with the extent of
vascularization and prognosis in many solid
tumors, and is predictive of resistance to radio-
therapy, chemotherapy, and endocrine therapy.
6-8
Furthermore, in vitro and in vivo experiments have
shown that increased VEGF expression is
associated with tumor growth and metastasis,
whereas inhibition of VEGF expression results in
suppression of tumor growth and tumor-induced
neoangiogenesis.
9 Clinical observations have
revealed that high levels of VEGF expression and
increased microvessel density in tumors are
associated with advanced-stage disease and worse
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prognosis for various types of tumors, including
stomach cancer.
6,7,10 Many studies have found a
correlation between VEGF expression and several
malignancies, such as stomach cancer and breast,
gastrointestinal, urinary tract, and ovarian
tumors.
11-15 In stomach cancer, VEGF has been
correlated with vascular involvement, lymph node
and liver metastasis.
16
Several SNPs in the VEGF gene have been
shown to affect the expression of the gene.
17 One
of these, the 936C > T polymorphism in the 3-
untranslated region (UTR) of the VEGF gene, was
shown to affect VEGF plasma levels, and carriers
of the VEGF 936T allele had significantly reduced
VEGF plasma levels.
18 Although some association
studies have been performed, the effect of VEGF
polymorphisms on the risk of stomach cancer has
not yet been evaluated.
Since VEGF is significant in the angiogenesis of
various types of tumors, it is reasonable to
hypothesize that VEGF is a good candidate for
determining the risk of developing stomach
cancer. To test this hypothesis, we investigated
genetic variations at the 936C > T polymorphic
site in the 3’-UTR of the VEGF gene in a Korean
population who have had stomach cancer.
PATIENTS AND METHODS
Subjects
A total of 154 patients (mean age ± SD, 58.05 ±
12.74 years) with stomach cancer diagnosed at
Bundang CHA Hospital, Pochon CHA University,
from July 1999 to June 2004, were enrolled in this
study. The diagnosis and staging of stomach
cancer were assessed according to the Lauren
classification.
19 Among stomach cancer patients,
there were 91 men (age 57.76 ± 12.31 years; range,
30 - 88 years) and 63 women (age 58.46 ± 13.42
years; range, 28 - 81 years). Ninety-nine patients
(age 59.85 ± 11.45 years; range, 28 - 88 years) had
intestinal subtype stomach cancer and 55 patients
(age 54.80 ± 14.32 years; range, 29 - 81 years) had
diffuse-subtype stomach cancer. The control group
consisted of 229 individuals (age 59.57 ± 11.80
years; range, 31 - 91 years) who were randomly
selected through health screening to exclude those
with a history of thrombotic diseases or cancer.
This study was approved by the Institutional
Review Board of Pochon CHA University, Korea.
VEGF genotyping
Genomic DNA was extracted from peripheral
blood lymphocytes by proteinase K digestion and
phenol/chloroform extraction. The VEGF 936C >
T (rs3025039) genotype polymorphisms were deter-
mined using the PCR-RFLP method. The PCR
primers used to detect the VEGF 936C > T poly-
morphism were 5’-AGG AAG AGG GAC TCT
GCG CAG AGC-3’ (forward) and 5’-TAA ATG
TAT GTA TGT GGG TGG GTG TGT CTA CAG
G-3’ (reverse). The PCR product was digested
overnight with NlaIII, the appropriate restriction
enzyme (New England BioLabs, Beverly, MA,
USA) for VEGF 936C > T genotyping. The VEGF
936T allele was cut into 2 fragments of 122 and 86
base pairs, whereas the VEGF 936C allele remained
uncut with a length of 208 base pairs.
Data analysis
Genotype frequencies of patients and healthy
control subjects were in Hardy-Weinberg equili-
brium, as tested by χ
2 test. Allele and genotype
frequencies between the case and control groups
were compared using χ
2 test and Fisher's exact test.
Odds ratios (ORs) and 95% confidence intervals
(95% CIs) were used as the measure of the strength
of association between the VEGF genotypes and
stomach cancer. Stratification analysis was used to
study subgroups by age and gender. StatsDirect
Statistical Software Version 2.4.4 (StatsDirect Ltd.,
Altrincham, UK) was used to calculate the
adjusted odds ratio (AOR) and 95% CI.
RESULTS
The median patient age was 60 years (range, 28-
88 years), and 91 patients (59.1%) were male.
There was no statistically significant difference in
age (p = 0.230) or gender distribution (p = 0.060)
between patients and controls (Table 1). The histo-
pathological classification after surgical resection
or biopsy included at least 2 main subtypes:VEGF Polymorphism and Stomach Cancer Risk
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intestinal type (n = 99, 64.3%) and diffuse type (n
= 55, 35.7%).
Tables 2 and 3 compare genotype frequencies of
the VEGF 936C > T polymorphism according to
the study group as a whole or by gender and age
between case and control groups. Genotypes were
in Hardy-Weinberg equilibrium in both the study
and control groups (p = 0.241). The distribution of
genotypes with the T allele at the VEGF 936C >
T polymorphism was significantly different
between the control and case groups (936CT,
AOR, 2.007; 95% CI, 1.277 - 3.156; 936TT, AOR,
4.790; 95% CI, 1.174 - 19.539; 936CT + TT, AOR,
2.147; 95% CI, 1.382 - 3.337; Table 2). Frequencies
of the 936CT and 936CT+TT genotypes in patients
were associated with increased risk for stomach
cancer in females (OR, 3.049; 95% CI, 1.568 - 5.930;
p = 0.001 and OR, 3.132; 95% CI, 1.638 - 5.990; p =
0.001; Table 3) when stratified by gender. When
the data were stratified by age, the association
remained in patients who were less than 55 years
old (936CT, OR, 3.306; 95% CI, 1.413 - 7.732; p =
0.006, 936CT + TT, OR, 3.967; 95% CI, 1.729 - 9.104;
p = 0.001).
Moreover, in females with diffuse-subtype
stomach cancer, the 936CT and 936CT + TT geno-
types were associated with increased risk for
stomach cancer (936CT, OR, 4.889; 95% CI, 1.970 -
12.14; p = 0.001, 936CT + TT, OR, 5.462; 95% CI,
2.266 - 13.17; p = 0.000) (Table 5). For intestinal-
subtype stomach cancer, however, there was no
significant difference in the genotype frequencies
between the 2 groups (Table 4).
DISCUSSION
Angiogenesis is essential for tumor growth and
plays a critical role in the invasion and metastasis
of tumor cells. It is regulated by many growth
Table 2. Comparison of Genotype Frequencies of the Vascular Endothelial Growth Factor 936C > T
Polymorphism in Patients with Stomach Cancer and Controls
Genotype Controls (%) Cases (%) OR (95% CI) AOR* (95% CI)
CC 169 (73.8) 89 (57.8) 1.0 (-) 1.0 (-)
CT 57 (24.9) 58 (37.7) 1.932 (1.236 - 3.021) 2.007 (1.277 - 3.156)
TT 3 (1.3) 7 (4.5) 4.431 (1.118 - 17.56) 4.790 (1.174 - 19.539)
CT+TT 60 (26.2) 65 (42.2) 2.057 (1.332 - 3.178) 2.147 (1.382 -3.337)
T allele 0.138 0.234 - -
OR, odds ratio; AOR, adjusted odds ratio.
*Adjusted by age and gender.
Table 1. Baseline Characteristics in Patients with Stomach Cancer and Controls
Controls (n = 229) Stomach cancer (n = 154) p value
Age (yrs, mean ± SD) 59.57 ± 11.80 58.05 ± 12.74 0.230
Male (%) 112 (48.9) 9 1(59.1) 0.060
Stage (%)
I - 60 (39.7) -
II - 28 (18.5) -
III - 29 (19.2) -
IV - 34 (22.5) 0.250
Smoking (%) 21/199 (10.6) 70/85 (82.4) < 0.0001Su Jin Bae, et al.
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factors, among which VEGF plays a central role
and serves as an important prognostic factor in a
variety of tumors, including stomach cancer. The
role of genetic polymorphisms, which are important
determinants of endogenous causes of cancer, in
the risk of stomach cancer has attracted increasing
interest due to advances in DNA analysis
technologies and knowledge of the human
genome. VEGF and its family play a critical role
in tumor-related angiogenesis, and several func-
tional polymorphisms in the VEGF gene have
already been reported to be associated with VEGF
gene expression or an increased risk of solid
tumors, making them potential predictive markers
for clinical outcome.
7,20-24 For example, the less
common T allele of the 936C > T polymorphism in
the 3’-untranslated region of the VEGF gene is
correlated with lower VEGF levels.
20 The con-
tribution of this polymorphism to oncogenesis has
been investigated in several types of cancer but
Table 3. Comparison of Subtype Frequencies of the Vascular Endothelial Growth Factor 936C > T
Polymorphism in Patients with Stomach Cancer and Controls
Genotype Controls (%) Cases (%) OR (95% CI) p value
Male
CC 81 (72.3) 58 (63.7) 1.0 (-) -
CT 30 (26.8) 29 (31.9) 1.350 (0.732 - 2.489) 0.352
TT 1 (0.9) 4 (4.4) 5.586 (0.608 - 51.31) 0.165
CT + TT 31 (27.7) 33 (36.3) 1.487 (0.8200 - 2.696) 0.225
T allele 0.143 0.204 - -
Female
CC 88 (75.2) 31 (49.2) 1.0 (-) -
CT 27 (23.1) 29 (46.0) 3.049 (1.568 - 5.930) 0.001
TT 2 (1.7) 3 (4.8) 4.258 (0.679 - 26.70) 0.126
CT + TT 29 (24.8) 32 (50.8) 3.132 (1.638 - 5.990) 0.001
T allele 0.132 0.278 - -
55 yrs
CC 109 (69.0) 56 (57.7) 1.0 (-) -
CT 46 (29.1) 38 (39.2) 1.608 (0.940 - 2.751) 0.097
TT 3 (1.9) 3 (3.1) 1.946 (0.380 - 9.962) 0.417
CT + TT 49 (31.0) 41 (42.3) 1.629 (0.963 - 2.754) 0.080
T allele 0.165 0.227 - -
< 55 yrs
CC 60 (84.5) 33 (57.9) 1.0 (-) -
CT 11 (15.5) 20 (35.1) 3.306 (1.413 - 7.732) 0.006
TT 0 (0.0) 4 (7.0) - -
CT + TT 11 (15.5) 24 (42.1) 3.967 (1.729 - 9.104) 0.001
T allele 0.077 0.246 - -
OR, odds ratio.VEGF Polymorphism and Stomach Cancer Risk
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not in stomach cancer until now to the our best
knowledge.
6,10,20,25-28
Based on the involvement of VEGF in the risk
of advanced-stage cancer through tumor growth
and metastasis of several types of cancer, in-
cluding stomach cancer, we evaluated the
relationship between the VEGF 936C > T polymor-
phism and stomach cancer in a Korean patient
case-control study. In the present study, the VEGF
936T allele was found to be associated with
Table 4. Comparison of Genotype Frequencies of the Vascular Endothelial Growth Factor 936C > T
Polymorphism in Patients with Intestinal-type Stomach Cancer and Controls
Genotype Controls (%) Cases (%) OR (95% CI) p value
CC 169 (73.8) 65 (65.7) 1.0 (-) -
CT 57 (24.9) 33 (33.3) 1.505 (0.899 - 2.521) 0.138
TT 3 (1.3) 1 (1.0) 0.867 (0.088 - 8.488) 1.000
CT + TT 60 (26.2) 34 (34.3) 1.473 (0.886 - 2.451) 0.145
T allele 0.138 0.177
Male
CC 81 (72.3) 44 (68.8) 1.0 (-) -
CT 30 (26.8) 19 (29.7) 1.166 (0.590 - 2.306) 0.727
TT 1 (0.9) 1 (1.6) 1.841 (0.112 - 30.17) 1.000
CT + TT 31 (27.7) 20 (31.3) 1.188 (0.607 - 2.325) 0.610
T allele 0.143 0.165
Female
CC 88 (75.2) 21 (60.0) 1.0 (-) -
CT 27 (23.1) 14 (40.0) 2.173 (0.974 - 4.847) 0.082
TT 2 (1.7) 0 (0.0) - -
CT + TT 29 (24.8) 14 (40.0) 2.023 (0.913 - 4.485) 0.090
T allele 0.132 0.200
55 yrs
CC 109 (69.0) 44 (64.7) 1.0 (-) -
CT 46 (29.1) 23 (33.8) 1.239 (0.672 - 2.282) 0.529
TT 3 (1.9) 1 (1.5) 0.826 (0.084 - 8.160) 1.000
CT + TT 49 (31.0) 24 (35.3) 1.213 (0.665 - 2.213) 0.538
T allele 0.165 0.184
55 yrs
CC 60 (84.5) 21 (67.7) 1.0 (-) -
CT 11 (15.5) 10 (32.3) 2.597 (0.965 - 6.993) 0.066
CT + TT 11 (15.5) 10 (32.3) 2.597 (0.965 - 6.993) 0.066
T allele 0.077 0.162
OR, odds ratio.Su Jin Bae, et al.
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increased risk for stomach cancer not only overall
but also in female subjects and subjects less than
55 years old when stratified by gender and age.
Several attempts to classify stomach cancer have
been made in the past decades. The most
successful and widely used classification is by
Table 5. Comparison of Genotype Frequencies of the Vascular Endothelial Growth Factor 936C > T
Polymorphism in Patients with Diffuse-type Stomach Cancer and Controls
Genotype Controls (%) Cases (%) OR (95% CI) p value
CC 169 (73.8) 24 (43.6) 1.0 (-) -
CT 57 (24.9) 25 (45.5) 3.088 (1.636 - 5.832) 0.001
TT 3 (1.3) 6 (10.9) 14.08 (3.301 - 60.08) 0.000
CT + TT 60 (26.2) 31 (56.4) 3.638 (1.979 - 6.689) 0.000
T allele 0.138 0.337
Male
CC 81 (72.3) 14 (51.9) 1.0 (-) -
CT 30 (26.8) 10 (37.0) 1.929 (0.774 - 4.808) 0.217
TT 1 (0.9) 3 (11.1) 17.36 (1.682 - 179.1) 0.015
CT + TT 31 (27.7) 13 (48.1) 2.426 (1.026 - 5.740) 0.063
T allele 0.143 0.296
Female
CC 88 (75.2) 10 (35.7) 1.0 (-) -
CT 27 (23.1) 15 (53.6) 4.889 (1.970 - 12.14) 0.001
TT 2 (1.7) 3 (10.7) 13.20 (1.964 - 88.74) 0.014
CT + TT 29 (24.8) 18 (64.3) 5.462 (2.266 - 13.17) 0.000
T allele 0.132 0.375
55 yrs
CC 109 (69.0) 12 (41.4) 1.0 (-) -
CT 46 (29.1) 15 (51.7) 2.962 (1.287 - 6.819) 0.014
TT 3 (1.9) 2 (6.9) 6.056 (0.918 - 39.94) 0.095
CT + TT 49 (31.0) 17 (58.6) 3.151 (1.398 - 7.101) 0.006
T allele 0.165 0.328
55 yrs
CC 60 (84.5) 12 (46.2) 1.0 (-) -
CT 11 (15.5) 10 (38.5) 4.545 (1.579 - 13.09) 0.007
TT 0 (0.0) 4 (15.4) - -
CT + TT 11 (15.5) 14 (53.8) 6.364 (2.331 - 17.37) 0.000
T allele 0.077 0.347
OR, odds ratio.VEGF Polymorphism and Stomach Cancer Risk
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Lauren, who distinguished 2 main cancer
pathogeneses, diffuse and intestinal subtypes, by
microscopic morphology alone. These 2 subtypes
clearly appear as clinical and epidemiological by
dissimilar entities. Here, we analyzed samples
from each patient according to the main differ-
ences in epidemiology, histopathology, and
molecular pathology of the 2 main subtypes of
stomach cancer based on the Lauren classifica-
tion.
29 There was no significant difference in the
genotype frequencies with intestinal-subtype
stomach cancer between the control and patient
groups. However, despite the relatively small
number of individuals in this study, highly
significant differences were noted with diffuse-
subtype stomach cancer between patients and
controls.
Surprisingly, stomach cancer in women is
associated with some genotypes of the VEGF 936C
> T polymorphism in this study. These trends
remained in women with diffuse-subtype stomach
cancer, even when the data were stratified by the
Lauren classification. That is, the association was
gender-specific, suggesting that VEGF production
according to VEGF 936C > T genotype might
differ between men and women. In addition, the
association was also specific for the histological
subtype of the stomach tumor, indicating that
VEGF production depends on the histological
subtype of the stomach tumor.
Our results strongly indicate that the T allele is
linked to an increased risk for stomach cancer,
despite being associated with lower circulating
levels of VEGF. It may, therefore, be assumed that
high VEGF levels are not a prerequisite for
stomach cancer susceptibility. Similarly, in
gliomas, low-expression VEGF genotypes coexist
with high VEGF levels in patients but not in
healthy controls.
30 High VEGF expression is
attributed to independent cancer and tumor
stroma production.
30
The findings of this study clearly demonstrate
that the low-expression T allele is associated with
an increased stomach cancer risk, however, the
underlying mechanism might not involve
angiogenesis but rather other VEGF-related
functions such as thrombosis. As previously
mentioned, in accordance with our results, a
significant increase in the T allele frequency has
been found in cancer patients with thrombotic
complications compared to healthy controls and
non-thrombotic cancer patients.
31 This association
has been reported in many cases, while the 936TT
genotype is associated with larger tumors and
presence of metastases.
24 This study clearly
implicates the low-expression T allele with an
increased risk of stomach cancer.
In cancer patients, additional risk factors for
thrombotic complications raise close relationships
between tumors and activation of blood coagula-
tion. Tumor and tumor-associated endothelial
cells are able to produce and release some
molecules,
32 and one of the molecules is VEGF,
which is a the well-characterized regulator of
angiogenesis. VEGF also affects hemostasis of
endothelial cells. VEGF has a prothrombotic effect
on endothelial cells, thus encouraging tissue factor
expression and additionally platelet activation.
33
Polymorphisms of the VEGF gene have been
shown to correlate with variation in VEGF protein
production.
34 Other oral and colon cancer studies
have reported that low VEGF production of the
936C > T polymorphism is strongly associated
with increased cancer risk.
35,36
We were interested in studying VEGF 936C > T
polymorphisms in the Korean population because
it has a relatively homogeneous ethnic origin in
contrast to the more heterogeneous characteristics
of ethnic groups examined in previous studies.
36
The literature survey indicates that the frequency
of VEGF 936T allele among healthy controls was
0.138 in Koreans and 0.157 in Japanese, indicating
that the allele ratio was similar among Asian
populations.
36,37 This study revealed that allele
frequencies of the VEGF 936C > T polymorphism
in our study control group were not significantly
different from other Asian populations. On the
other hand, there was a racial difference in the
frequency of the T allele: 0.167 in Canadians, 0.161
in Polish (only female group), 0.140 in Americans,
and 0.091 in Germans.
6,26,38,39 Earlier differences in
the literature might have been results may be due
to different genetic backgrounds.
Functional polymorphisms, which affect the
regulation of gene expression, can contribute to
differences in susceptibility to and severity of a
disease between individuals. The effect may be
seen with polymorphism alone or in combinationSu Jin Bae, et al.
Yonsei Med J Vol. 49, No. 5, 2008
with other polymorphisms. These functional
polymorphisms may result in altered transcription
factor recognition sites, which subsequently affect
transcriptional activation and alter protein pro-
duction.
37 Haplotype analysis, which is currently
the focus of intense genetic research efforts, will
make risk estimates more specific than single
locus analyses.
40 Identification of associations
between candidate genes and disease will be one
of the main objectives in the development of
personalized and interactive medicine.
In conclusion, our present findings indicate that
the VEGF 936C> T polymorphism may be a useful
indicator of susceptibility to stomach cancer.
Large-scale genetic studies including haplotype
analyses may be needed to improve statistical
power. In addition, studies of other VEGF sequence
variants and their biological functions are also
needed to determine the risk of stomach cancer.
Since genetic polymorphisms often vary between
ethnic groups, further studies are needed to
clarify the association between VEGF polymor-
phisms and stomach cancer in diverse ethnic
populations.
REFERENCES
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer
statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Kong U, Koo J, Choi K, Park J, Chang H. The expres-
sion of GAGE gene can predict aggressive biologic
behavior of intestinal type of stomach cancer. Hepato-
gastroenterology 2004;51:1519-23.
3. Yasui W, Ito H, Yoshida K, Tahara E. Biological
malignancy in human gastric carcinoma--molecular
aspects. Gan To Kagaku Ryoho 1991;18:927-33.
4. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I,
Mizutani T, et al. Clinical significance of epidermal
growth factor (EGF), EGF receptor, and c-erbB-2 in
human gastric cancer. Cancer 1995;75 (6 Suppl):1418-25.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF
and its receptors. Nat Med 2003;9:669-76.
6. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska
E, Klaes R, et al. Vascular endothelial growth factor
polymorphisms in relation to breast cancer develop-
ment and prognosis. Clin Cancer Res 2005;11:3647-53.
7. Koukourakis MI, Papazoglou D, Giatromanolaki A,
Bougioukas G, Maltezos E, Sivridis E. VEGF gene
sequence variation defines VEGF gene expression status
and angiogenic activity in non-small cell lung cancer.
Lung Cancer 2004;46:293-8.
8. Ferrara N. Vascular endothelial growth factors as a
target for anticancer therapy. Oncologist 2004;9 Suppl
1:2-10.
9. Ferrara N. VEGF and the quest for tumour angio-
genesis factors. Nat Rev Cancer 2002;2:795-803.
10. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, et
al. Association of genetic polymorphisms in the VEGF
gene with breast cancer survival. Cancer Res 2005;65:
5015-9.
11. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis
LM. Expression of vascular endothelial growth factor
and its receptor, KDR, correlates with vascularity,
metastasis, and proliferation of human colon cancer.
Cancer Res 1995;55:3964-8.
12. Toi M, Hoshina S, Takayanagi T, Tominaga T. Asso-
ciation of vascular endothelial growth factor expression
with tumor angiogenesis and with early relapse in
primary breast cancer. Jpn J Cancer Res 1994;85:1045-9.
13. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau
EJ, Senger DR, et al. Expression of vascular permea-
bility factor (vascular endothelial growth factor) and its
receptors in adenocarcinomas of the gastrointestinal
tract. Cancer Res 1993;53:4727-35.
14. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau
EJ, Dvorak HF, et al. Increased expression of vascular
permeability factor (vascular endothelial growth factor)
and its receptors in kidney and bladder carcinomas.
Am J Pathol 1993;143:1255-62.
15. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S.
Vascular permeability factor gene expression in normal
and neoplastic human ovaries. Cancer Res 1994;54:276-
80.
16. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM,
Ogawa M, et al. Prognostic value of vascular endothelial
growth factor expression in gastric carcinoma. Cancer
1996;77:858-63.
17. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE.
Identification of polymorphisms within the vascular
endothelial growth factor (VEGF) gene: correlation
with variation in VEGF protein production. Cytokine
2000;12:1232-5.
18. Report of the National High Blood Pressure Education
Program Working Group on High Blood Pressure in
Pregnancy. Am J Obstet Gynecol 2000;183:S1-S22.
19. Vauhkonen M, Vauhkonen H, Sipponen P. Pathology
and molecular biology of gastric cancer. Best Pract Res
Clin Gastroenterol 2006;20:651-74.
20. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki
B, Wolf G, Wascher TC, et al. A common 936 C/T gene
polymorphism of vascular endothelial growth factor is
associated with decreased breast cancer risk. Int J
Cancer 2003;106:468-71.
21. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero
J, Desmet F, Marklund SL, et al. VEGF is a modifier
of amyotrophic lateral sclerosis in mice and humans
and protects motoneurons against ischemic death. Nat
Genet 2003;34:383-94.
22. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley
DP, Dowe A, et al. Influence of cytokine gene polymor-VEGF Polymorphism and Stomach Cancer Risk
Yonsei Med J Vol. 49, No. 5, 2008
phisms on the development of prostate cancer. Cancer
Res 2002;62:3369-72.
23. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay
HM, Hutchinson IV, et al. Vascular endothelial growth
factor gene polymorphisms are associated with acute
renal allograft rejection. J Am Soc Nephrol 2002;13:260-
4.
24. Tzanakis N, Gazouli M, Rallis G, Giannopoulos G,
Papaconstantinou I, Theodoropoulos G, et al. Vascular
endothelial growth factor polymorphisms in gastric
cancer development, prognosis, and survival. J Surg
Oncol 2006;94:624-30.
25. Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, et
al. Population-based case-control study of VEGF gene
polymorphisms and breast cancer risk among Chinese
women. Cancer Epidemiol Biomarkers Prev 2006;15:
1148-52.
26. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez
C, Stevens VL, et al. Polymorphisms in the vascular
endothelial growth factor gene and breast cancer in the
Cancer Prevention Study II cohort. Breast Cancer Res
2006;8:R22.
27. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L.
Association of VEGF genetic polymorphisms with
prostate carcinoma risk and clinical outcome. Cytokine
2006;35:21-8.
28. Abe A, Sato K, Habuchi T, Wang L, Li Z, Tsuchiya N,
et al. Single nucleotide polymorphisms in the 3'
untranslated region of vascular endothelial growth
factor gene in Japanese population with or without
renal cell carcinoma. Tohoku J Exp Med 2002;198:181-
90.
29. Vauhkonen M, Vauhkonen H, Sipponen P. Pathology
and molecular biology of gastric cancer. Best Pract Res
Clin Gastroenterol 2006;20:651-74.
30. Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S,
Pogliani S, et al. Genetic and plasma markers of venous
thromboembolism in patients with high grade glioma.
Clin Cancer Res 2004;10:1312-7.
31. Eroglu A, Gulec S, Akar N. Vascular endothelial
growth factor C936T polymorphism in cancer patients
with thrombosis. Am J Hematol 2006;82:174.
32. Pinedo HM. The role of VEGF in oncology: effects on
hemostasis and thrombosis. Pathophysiol Haemost
Thromb 2003;33 Suppl 1:11-2.
33. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ,
Gebbink MF, Pinedo HM. Vascular endothelial growth
factor-stimulated endothelial cells promote adhesion
and activation of platelets. Blood 2000;96:4216-21.
34. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V,
Hutchinson IV. Novel polymorphism in the promoter
and 5’ UTR regions of the human vascular endothelial
growth factor gene. Hum Immunol 1999;60:1245-9.
35. Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A,
Nkenke E, Nixon AM, et al. The low VEGF production
allele of the +936C/T polymorphism is strongly asso-
ciated with increased risk for oral cancer. J Cancer Res
Clin Oncol 2007;133:787-91.
36. Bae SJ, Kim JW, Kang H, Hwang SG, Oh D, Kim NK.
Gender-specific association between polymorphism of
vascular endothelial growth factor (VEGF 936C > T)
gene and colon cancer in Korea. Anticancer Res 2008;
28:1271-6.
37. Sakao S, Tatsumi K, Hashimoto T, Igari H, Shino Y,
Shirasawa H, et al. Vascular endothelial growth factor
and the risk of smoking-related COPD. Chest 2003;124:
323-7.
38. Butt C, Lim S, Greenwood C, Rahman P. VEGF, FGF1,
FGF2 and EGF gene polymorphisms and psoriatic
arthritis. BMC Musculoskelet Disord 2007;8:1.
39. Günesacar R, Opelz G, Erken E, Pelzl S, Döhler B,
Ruhenstroth A, et al. VEGF 936 C/T gene polymor-
phism in renal transplant recipients: association of the
T allele with good graft outcome. Hum Immunol
2007;68:599-602.
40. Clark AG. The role of haplotypes in candidate gene
studies. Genet Epidemiol 2004;27:321-33.